Table 2.
Number of BC* patients with different BC subtypes
| Breast cancer subtype | Number of cases | Percentage |
|---|---|---|
| Premenopausal | ||
| Luminal A | 44 | 25.14% |
| Her-2* positive | 23 | 13.14% |
| Luminal B (Her-2 positive) | 31 | 17.71% |
| Luminal B (Her-2 negative) | 45 | 25.71% |
| Triple-Negative Breast Cancer | 8 | 4.57% |
| In Situ Carcinoma | 17 | 9.71% |
| Postmenopausal | ||
| Luminal A | 25 | 13.66% |
| Her-2 positive | 35 | 19.13% |
| Luminal B (Her-2 positive) | 32 | 17.49% |
| Luminal B (Her-2 negative) | 33 | 18.03% |
| Triple-Negative Breast Cancer | 28 | 15.30% |
| In Situ Carcinoma | 9 | 4.92% |
*
Her-2, human epidermal growth factor receptor 2; BC, breast cancer.